Anavex Life

AVXL NASDAQ
2.750
+0.040
+1.48%
After Hours: 2.720 -0.03 -1.09% 19:34 08/19 EDT
Open
2.740
Prev Close
2.710
High
2.826
Low
2.610
Volume
216.40K
Avg Vol (3M)
530.43K
52 Week High
4.090
52 Week Low
1.250
% Turnover
0.41%
Market Cap
144.79M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Anavex Life AVXL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.
MORE >

Recently

Name
Price
%Change